Although the BETonRENAL trial is not scheduled to begin until mid Sept now, there is a huge amount of data being collected currently on CKD patients in the current BETonMACE Phase III trial? Up to 21 months worth now. There may be up to hundreds of CKD patients in this trial. I have heard that one patient started the trial with an eGFR of 18 and about 6 months later that patients eGFR was 34. According to one Nepherologist questioned after he heard this stat his comment was this company will make many billions on the renal side if this drug ever gets approved. When you look back on the charts used to value the company in their presentations earlier this year the single highest value was with the EMA, FDA and Renal all being approved. The path RVX is currently on takes them to the highest valuation.

I sense that the loan modification or payout will happen before 28 August even if just a day before. If it happens to be a PP that doesn't really bother me either. I think I remember the PP they did with Hepa and Eastern a couple of years ago being done at a premium to the market at the time. Why not this time if that route is taken? With the data they are collecting on CKD patients now it would actually be surprising to me if they didn't do some kind of partnering arrangement with the BETonRENAL trial.

Many of us have been in this story for quite a few years and are apprehensive about anything we hear about RVX. Try to keep in mind that the company has now 17 years of data to back up their claims. They are a long long way from where they were a number of years ago when making the same claims.

The balance of this year could be very exciting.

tada

dyodd